Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials

Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes, obesity & metabolism obesity & metabolism, 2023-08, Vol.25 (8), p.2388-2392
Hauptverfasser: Verma, Subodh, David, Jens‐Peter, Leiter, Lawrence A., Michelsen, Marie Mide, Rasmussen, Søren, Bhatt, Deepak L.
Format: Artikel
Sprache:eng
Schlagworte:
antidiabetic drug
Antidiabetics
Cardiovascular disease
Cardiovascular diseases
Clinical outcomes
Clinical trials
Diabetes
Diabetes mellitus (non-insulin dependent)
Disease prevention
Drug therapy
semaglutide
type 2 diabetes
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.15081